Antipsychotic drugs, menstrual regularity and osteoporosis risk.
This report summarizes the preliminary results of a study in progress, a survey of 200 women with schizophrenia in long-term treatment with antipsychotic medication. In the context of providing clinical service to these women (Seeman, 1997; Seeman and Cohen, 1998), we have begun to investigate the possibility of an association among related factors: type of antipsychotic drug use, the presence of amenorrhea, hyperprolactinemia and risk for osteoporosis (Biller et al., 1992; Grinspoon et al., 1999; Halbreich and Palter, 1996; More et al., 2001; Peuskens, 1997; Sowers et al., 1995).
Zhang-Wong
J H
JH
Mt. Sinai Hospital and Department of Psychiatry, Centre for Addiction and Mental Health, University of Toronto, 250 College Street, Toronto, Ontario, Canada M5T 1R8.
Seeman
M V
MV
D000328:Adult; D000568:Amenorrhea / Q000139:chemically induced*; D014150:Antipsychotic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000097:blood / Q000139:chemically induced* / Q000150:complications; D010024:Osteoporosis / Q000139:chemically induced* / Q000517:prevention & control; D012559:Schizophrenia / Q000188:drug therapy*
D014150:Antipsychotic Agents